Skip to main content
SpringerLink
Log in

Frontline Management of Acute Promyelocytic Leukemia

  • Chapter
  • First Online:
Pathogenesis and Treatment of Leukemia

  • 452 Accesses

Abstract

In the frontline management of acute promyelocytic leukemia (APL), prevention of early deaths and the selection of the optimal frontline induction strategies incorporating arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) are the more important factors in determining the outcome of APL. In this chapter, we discuss the problem of early deaths and principles in circumventing this important issue. Second, we discuss the optimal frontline induction regimens incorporating ATO and ATRA.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009;114(25):5126–35.

    PubMed  Google Scholar 

  2. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the north American intergroup protocol. Blood. 2002;100(13):4298–302.

    PubMed  Google Scholar 

  3. Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23(12):2248–58.

    PubMed  Google Scholar 

  4. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group. Blood. 2010;116(17):3171–9.

    PubMed  Google Scholar 

  5. Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009;27(16):2668–76.

    PubMed  Google Scholar 

  6. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94(10):3315–24.

    PubMed  Google Scholar 

  7. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852–60.

    PubMed  Google Scholar 

  8. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106(9):3342–7.

    PubMed  PubMed Central  Google Scholar 

  9. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: north American leukemia intergroup study C9710. Blood. 2010;116(19):3751–7.

    PubMed  PubMed Central  Google Scholar 

  10. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570–80; quiz 752.

    PubMed  Google Scholar 

  11. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–21.

    PubMed  Google Scholar 

  12. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–305.

    PubMed  Google Scholar 

  13. Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute Promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605–12.

    PubMed  Google Scholar 

  14. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275–83.

    PubMed  PubMed Central  Google Scholar 

  15. Au WY, Kumana CR, Kou M, Mak R, Chan GC, Lam CW, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood. 2003;102(1):407–8.

    PubMed  Google Scholar 

  16. Au WY, Li CK, Lee V, Yuen HL, Yau J, Chan GC, et al. Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients. Pediatr Blood Cancer. 2012;58(4):630–2.

    PubMed  Google Scholar 

  17. Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood. 2011;118(25):6535–43.

    PubMed  Google Scholar 

  18. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103(4):1237–43.

    PubMed  Google Scholar 

  19. Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, Milone G, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25):5137–46.

    PubMed  Google Scholar 

  20. Sanz MA, Montesinos P, Vellenga E, Rayon C, de la Serna J, Parody R, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Blood. 2008;112(8):3130–4.

    PubMed  Google Scholar 

  21. Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25):5137–46.

    PubMed  Google Scholar 

  22. Breccia M, Latagliata R, Cannella L, Minotti C, Meloni G, Lo-Coco F. Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica. 2010;95(5):853–4.

    PubMed  Google Scholar 

  23. McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97(1):133–6.

    PubMed  PubMed Central  Google Scholar 

  24. Chien N, Varghese C, Green TN, Chan G, Theakston E, Eaddy N, et al. Treatment outcomes of patients with acute promyelocytic leukaemia between 2000 and 2017, a retrospective, single Centre experience. Leuk Res. 2020;93:106358.

    PubMed  Google Scholar 

  25. Rahme R, Thomas X, Recher C, Vey N, Delaunay J, Deconinck E, et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014;28(12):2422–4.

    PubMed  Google Scholar 

  26. Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248–54.

    PubMed  PubMed Central  Google Scholar 

  27. Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, et al. Improving outcomes of acute promyelocytic leukemia in the current era: analysis of the SEER database. J Natl Compr Cancer Netw. 2020;18(2):169–75.

    Google Scholar 

  28. Paulson K, Serebrin A, Lambert P, Bergeron J, Everett J, Kew A, et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol. 2014;166(5):660–6.

    PubMed  Google Scholar 

  29. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Mollgard L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish adult acute leukemia registry. Leukemia. 2011;25(7):1128–34.

    PubMed  Google Scholar 

  30. Zhu HH, Ma YF, Yu K, Ouyang GF, Luo WD, Pei RZ, et al. Early death and survival of patients with acute Promyelocytic leukemia in ATRA plus arsenic era: a population-based study. Front Oncol. 2021;11:762653.

    PubMed  PubMed Central  Google Scholar 

  31. Gill H, Yung Y, Chu HT, Au WY, Yip PK, Lee E, et al. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study. Blood Adv. 2021;5(14):2829–38.

    PubMed  PubMed Central  Google Scholar 

  32. Jacomo RH, Melo RA, Souto FR, de Mattos ER, de Oliveira CT, Fagundes EM, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92(10):1431–2.

    PubMed  Google Scholar 

  33. Serefhanoglu S, Buyukasik Y, Goker H, Sayinalp N, Haznedaroglu IC, Aksu S, et al. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res. 2010;34(12):e317–9.

    PubMed  Google Scholar 

  34. Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975–2008. Cancer. 2012;118(23):5811–8.

    PubMed  Google Scholar 

  35. Jeddi R, Ghedira H, Ben Amor R, Ben Abdennebi Y, Karima K, Mohamed Z, et al. Treatment of acute promyelocytic leukemia with AIDA based regimen. Update of a Tunisian single center study. Mediterr J Hematol Infect Dis. 2011;3(1):e2011033.

    PubMed  PubMed Central  Google Scholar 

  36. Pagoni M, Garofalaki M, Panitsas F, Manola K, Psarra K, Economopoulos P, et al. Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic acid era. Mediterr J Hematol Infect Dis. 2011;3(1):e2011053.

    PubMed  PubMed Central  Google Scholar 

  37. Imagawa J, Harada Y, Shimomura T, Tanaka H, Okikawa Y, Harada H. High early death rate in elderly patients with acute promyelocytic leukemia treated with all-trans retinoic acid combined chemotherapy. Int J Hematol. 2013;98(2):264–6.

    PubMed  Google Scholar 

  38. Karim F, Shaikh U, Adil SN, Khurshid M. Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care Centre. Singap Med J. 2014;55(8):443–7.

    Google Scholar 

  39. Bajpai J, Sharma A, Kumar L, Dabkara D, Raina V, Kochupillai V, et al. Acute promyelocytic leukemia: an experience from a tertiary care centre in North India. Indian J Cancer. 2011;48(3):316–22.

    PubMed  Google Scholar 

  40. de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395–402.

    PubMed  Google Scholar 

  41. Micol JB, Raffoux E, Boissel N, Lengliné E, Canet E, Daniel MT, et al. Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. Eur J Cancer. 2014;50(6):1159–68.

    PubMed  Google Scholar 

  42. Sanz MA, Fenaux P, Tallman MS, Estey EH, Lowenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630–43.

    PubMed  PubMed Central  Google Scholar 

  43. Kayser S, Rahme R, Martinez-Cuadron D, Ghiaur G, Thomas X, Sobas M, et al. Outcome of older (>/=70 years) APL patients frontline treated with or without arsenic trioxide-an international collaborative study. Leukemia. 2020;34(9):2333–41.

    PubMed  PubMed Central  Google Scholar 

  44. Jillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia. Blood Rev. 2018;32(2):89–95.

    PubMed  Google Scholar 

  45. Naymagon L, Moshier E, Tremblay D, Mascarenhas J. Predictors of early hemorrhage in acute promyelocytic leukemia. Leuk Lymphoma. 2019;60(10):2394–403.

    PubMed  Google Scholar 

  46. Chang H, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol. 2012;88(4):321–8.

    PubMed  Google Scholar 

  47. Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017;129(13):1763–7.

    PubMed  PubMed Central  Google Scholar 

  48. Hou W, Zhang Y, Jin B, Cao W, Lu M, Yan L, et al. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone. Blood Cells Mol Dis. 2019;79:102351.

    PubMed  Google Scholar 

  49. Gurnari C, Breccia M, Di Giuliano F, Scalzulli E, Divona M, Piciocchi A, et al. Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. Br J Haematol. 2021;193(1):129–32.

    PubMed  Google Scholar 

  50. Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013;37(9):1004–9.

    PubMed  Google Scholar 

  51. Sun J, Zhu J, Zhou D, Zhu L, Yang X, Xie M, et al. Factors affecting early death and survival of patients with acute Promyelocytic leukemia treated with ATRA-based therapy regimens. Clin Lymphoma Myeloma Leuk. 2019;19(1):e63–70.

    PubMed  Google Scholar 

  52. Mantha S, Tallman MS, Devlin SM, Soff GA. Predictive factors of fatal bleeding in acute promyelocytic leukemia. Thromb Res. 2018;164(Suppl 1):S98–S102.

    PubMed  Google Scholar 

  53. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340(13):994–1004.

    PubMed  Google Scholar 

  54. Liu Y, Wang Z, Jiang M, Dai L, Zhang W, Wu D, et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res. 2011;35(7):879–84.

    PubMed  Google Scholar 

  55. Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood. 1994;84(11):3843–9.

    PubMed  Google Scholar 

  56. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia. 1995;9(5):774–8.

    PubMed  Google Scholar 

  57. De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;92(8):2712–8.

    PubMed  Google Scholar 

  58. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95(1):90–5.

    PubMed  Google Scholar 

  59. Montesinos P, Bergua JM, Vellenga E, Rayon C, Parody R, de la Serna J, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775–83.

    PubMed  Google Scholar 

  60. Leblebjian H, DeAngelo DJ, Skirvin JA, Stone RM, Wadleigh M, Werner L, et al. Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res. 2013;37(7):747–51.

    PubMed  Google Scholar 

  61. Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019;187(2):157–62.

    PubMed  Google Scholar 

  62. Olwill SA, McGlynn H, Gilmore WS, Alexander HD. All-trans retinoic acid-induced downregulation of annexin II expression in myeloid leukaemia cell lines is not confined to acute promyelocytic leukaemia. Br J Haematol. 2005;131(2):258–64.

    PubMed  Google Scholar 

  63. Zhang X, Zhou H, Wang J, Yang L, Hu Y, Shen G, et al. Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator. Thromb Res. 2002;106(1):63–70.

    PubMed  Google Scholar 

  64. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst. 1998;90(2):124–33.

    PubMed  Google Scholar 

  65. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94(8):3978–83.

    PubMed  PubMed Central  Google Scholar 

  66. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med. 1999;189(7):1043–52.

    PubMed  PubMed Central  Google Scholar 

  67. de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10(11):775–83.

    PubMed  Google Scholar 

  68. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469–73.

    PubMed  Google Scholar 

  69. Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27(4):504–10.

    PubMed  Google Scholar 

  70. Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 2012;97(2):227–34.

    PubMed  PubMed Central  Google Scholar 

  71. Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31(33):4215–21.

    PubMed  Google Scholar 

  72. Gill H, Kumana CR, Yim R, Hwang YY, Chan TSY, Yip SF, et al. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: a 5-year prospective study. Cancer. 2019;125(17):3001–12.

    PubMed  Google Scholar 

  73. Kumana CR, Mak R, Kwong YL, Gill H. Resurrection of oral arsenic trioxide for treating acute promyelocytic leukaemia: a historical account from bedside to bench to bedside. Front Oncol. 2020;10:1294.

    PubMed  PubMed Central  Google Scholar 

  74. Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106(12):3768–76.

    PubMed  Google Scholar 

  75. Beitinjaneh A, Jang S, Roukoz H, Majhail NS. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 2010;34(7):831–6.

    PubMed  Google Scholar 

  76. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 2010;18(1):88–98.

    PubMed  Google Scholar 

  77. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 2010;328(5975):240–3.

    PubMed  Google Scholar 

  78. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10(5):547–55.

    PubMed  Google Scholar 

  79. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol. 2008;10(5):538–46.

    PubMed  Google Scholar 

  80. Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A. 2000;97(18):10173–8.

    PubMed  PubMed Central  Google Scholar 

  81. Dos Santos GA, Kats L, Pandolfi PP. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med. 2013;210(13):2793–802.

    PubMed  PubMed Central  Google Scholar 

  82. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999;93(1):268–77.

    PubMed  Google Scholar 

  83. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood. 2001;98(3):805–13.

    PubMed  Google Scholar 

  84. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res. 2002;8(12):3658–68.

    PubMed  Google Scholar 

  85. Yedjou CG, Rogers C, Brown E, Tchounwou PB. Differential effect of ascorbic acid and n-acetyl-L-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells. J Biochem Mol Toxicol. 2008;22(2):85–92.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China

    Harinder Gill

Authors
  1. Harinder Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harinder Gill .

Editor information

Editors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Harinder Gill

  2. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Yok-Lam Kwong

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gill, H. (2023). Frontline Management of Acute Promyelocytic Leukemia. In: Gill, H., Kwong, YL. (eds) Pathogenesis and Treatment of Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-99-3810-0_17

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-3810-0_17

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-3809-4

  • Online ISBN: 978-981-99-3810-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation